{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:26:14Z","timestamp":1778624774743,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE15-0038"],"award-info":[{"award-number":["ANR-22-CE15-0038"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-24-CE18-2934"],"award-info":[{"award-number":["ANR-24-CE18-2934"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019899","name":"Alliance Nationale pour les Sciences de la Vie et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","award":["TAQK18773"],"award-info":[{"award-number":["TAQK18773"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["12560"],"award-info":[{"award-number":["12560"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ajt.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:17:23Z","timestamp":1747163843000},"page":"2127-2141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1114-6385","authenticated-orcid":false,"given":"Antoine","family":"Tichadou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4636-2192","authenticated-orcid":false,"given":"Eden","family":"Lebrault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2610-9915","authenticated-orcid":false,"given":"Assia","family":"Samri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-8684","authenticated-orcid":false,"given":"Marine","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-7577","authenticated-orcid":false,"given":"C\u00e9cilia","family":"Nakid-Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4737-1035","authenticated-orcid":false,"given":"David","family":"Lavergne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oulfata","family":"Mze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noureddine","family":"Balegroune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-0532","authenticated-orcid":false,"given":"Xiaozhen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-0470","authenticated-orcid":false,"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1578-072X","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Guihot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-8049","authenticated-orcid":false,"given":"Patrick","family":"Legembre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-9428","authenticated-orcid":false,"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajt.2025.05.010_bib1","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ijc.33934","article-title":"Cancer risk and mortality after solid organ transplantation: a population-based 30-year cohort study in Finland","volume":"150","author":"Friman","year":"2022","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ajt.2025.05.010_bib2","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ajt.2025.05.010_bib3","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41375-022-01667-1","article-title":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell post-transplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial","volume":"36","author":"Zimmermann","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ajt.2025.05.010_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-020-04056-9","article-title":"Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients","volume":"100","author":"Gonz\u00e1lez-Barca","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.ajt.2025.05.010_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ajt.2025.05.010_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ajt.2025.05.010_bib7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ajt.2025.05.010_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.immuni.2009.01.001","article-title":"The many roles of FAS receptor signaling in the immune system","volume":"30","author":"Strasser","year":"2009","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ajt.2025.05.010_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0968-0004(01)01995-8","article-title":"The molecular architecture of the TNF superfamily","volume":"27","author":"Bodmer","year":"2002","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"10.1016\/j.ajt.2025.05.010_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189004","article-title":"CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways","volume":"1878","author":"Haymour","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ajt.2025.05.010_bib11","doi-asserted-by":"crossref","unstructured":"Yi F, Cohen T, Zimmerman N, et al. CAR-engineered lymphocyte persistence is governed by a FAS ligand\/FAS auto-regulatory circuit. Preprint. Posted online March 1, 2024. bioRxiv. 2024.02.26.582108.","DOI":"10.1101\/2024.02.26.582108"},{"issue":"1","key":"10.1016\/j.ajt.2025.05.010_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ajt.2025.05.010_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ajt.2025.05.010_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29440","article-title":"Membrane-bound CD95 ligand modulates CD19-mediated B cell receptor signaling and EBV activation","volume":"96","author":"Liu","year":"2024","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.ajt.2025.05.010_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2016.06.028","article-title":"CD95-mediated calcium signaling promotes T helper 17 trafficking to inflamed organs in lupus-prone mice","volume":"45","author":"Poissonnier","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.ajt.2025.05.010_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41589-018-0162-9","article-title":"Disrupting the CD95-PLC\u03b31 interaction prevents Th17-driven inflammation","volume":"14","author":"Poissonnier","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"10","key":"10.1016\/j.ajt.2025.05.010_bib17","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.4049\/jimmunol.165.10.5884","article-title":"Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer","volume":"165","author":"Waku","year":"2000","journal-title":"J Immunol."},{"issue":"1","key":"10.1016\/j.ajt.2025.05.010_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijc.20538","article-title":"CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo","volume":"113","author":"Igney","year":"2005","journal-title":"Int J Cancer"},{"issue":"7264","key":"10.1016\/j.ajt.2025.05.010_bib19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nature08402","article-title":"Membrane-bound Fas ligand only is essential for Fas-induced apoptosis","volume":"461","author":"O\u2019Reilly","year":"2009","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ajt.2025.05.010_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001090","article-title":"The naturally processed CD95L elicits a c-yes\/calcium\/PI3K-driven cell migration pathway","volume":"9","author":"Tauzin","year":"2011","journal-title":"PLoS Biol"},{"issue":"8","key":"10.1016\/j.ajt.2025.05.010_bib21","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/ajt.16547","article-title":"Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders","volume":"21","author":"Nakid-Cordero","year":"2021","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2025.05.010_bib22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ajt.13086","article-title":"International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial","volume":"15","author":"Trappe","year":"2015","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2025.05.010_bib23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ajt.2025.05.010_bib24","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ajt.2025.05.010_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ajt.2025.05.010_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13244-019-0726-6","article-title":"Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential","volume":"10","author":"White","year":"2019","journal-title":"Insights Imaging"},{"issue":"2","key":"10.1016\/j.ajt.2025.05.010_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188596","article-title":"Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?","volume":"1876","author":"Kurma","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ajt.2025.05.010_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074099","article-title":"Role of metalloproteases in the CD95 signaling pathways","volume":"13","author":"Devel","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ajt.2025.05.010_bib29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/eji.202048941","article-title":"Deep phenotypical characterization of human CD3+ CD56+ T cells by mass cytometry","volume":"51","author":"Romero-Olmedo","year":"2021","journal-title":"Eur J Immunol"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525002643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525002643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:34:50Z","timestamp":1778621690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613525002643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1600613525002643"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2025.05.010","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}